A 36-year-old man with HIV infection developed a reaction compatible with an abacavir hypersensitivity reaction after switching from the twice-daily to the once-daily formulation. The switch was determined by a more convenient intake. The patient was treated with abacavir twice-daily plus lamivudine and efavirenz for more than 5 years with no side effects. At the time of this change, his CD4 count was 1069 cell/mm3 and HIV-RNA undetectable. Our case suggests that patients should be carefully monitored after switching, and warned about the potential effects.
Abacavir hypersensitivity reaction after switching from the twice-daily to the once-daily formulation / C. Gervasoni, O. Vigano, E. Gianelli, M. Ortu, M. Galli, S. Rusconi. - In: AIDS PATIENT CARE AND STDS. - ISSN 1087-2914. - 21:1(2007 Jan), pp. 1-3.
Abacavir hypersensitivity reaction after switching from the twice-daily to the once-daily formulation
O. ViganoSecondo
;E. Gianelli;M. Ortu;M. GalliPenultimo
;S. RusconiUltimo
2007
Abstract
A 36-year-old man with HIV infection developed a reaction compatible with an abacavir hypersensitivity reaction after switching from the twice-daily to the once-daily formulation. The switch was determined by a more convenient intake. The patient was treated with abacavir twice-daily plus lamivudine and efavirenz for more than 5 years with no side effects. At the time of this change, his CD4 count was 1069 cell/mm3 and HIV-RNA undetectable. Our case suggests that patients should be carefully monitored after switching, and warned about the potential effects.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
